PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 149
DOI: 10.4103/sajc.sajc_400_18
Letter to the Editor

Severe hypoglycemia with trastuzumab: An unseen adverse event

Authors

  • B. P. Amrith

    Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

  • Parveen Jain

    Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

  • Krushna A. Chaudhari

    Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

  • Mansi Sharma

    Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

  • Ullas Batra

    Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

Financial support and sponsorship Nil.
Weitere Informationen
Auch verfügbar auf
 als PDF herunterladen Lizenzen und Reprints
Preview Container


Publikationsverlauf

Artikel online veröffentlicht:
21. Dezember 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hudis CA. Trastuzumab – Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
  • 2 FDA Label-Trastuzumab. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf. [Last accessed on 2018 Nov 15].
  • 3 Herceptin and Hypoglycemia – From FDA Reports, eHealthME; November, 2018. Available from: https://www.ehealthme.com/ds/herceptin/hypoglycemia. [Last accessed on 2018 Nov 15].